UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 102

Sortiert nach

Platinum Resistance: The Role of DNA Repair Pathways

Clinical cancer research, 2008-03, Vol.14 (5), p.1291-1295

2008

Volltextzugriff (PDF)

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Journal of clinical oncology, 2017-04, Vol.35 (10), p.1112-1118

2017

Volltextzugriff (PDF)

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Gynecologic oncology, 2020-05, Vol.157 (2), p.379-385

2020

Volltextzugriff (PDF)

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-10, Vol.23 (19), p.5703-5710

2017

Volltextzugriff (PDF)

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

The New England journal of medicine, 2016-02, Vol.374 (8), p.738-748

2016

Volltextzugriff (PDF)

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

The oncologist (Dayton, Ohio), 2019-04, Vol.24 (4), p.425-429

2019

Volltextzugriff (PDF)

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

Gynecologic oncology, 2015-02, Vol.136 (2), p.246-253

2015

Volltextzugriff (PDF)

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

Gynecologic oncology, 2021-11, Vol.163 (2), p.246-253

2021

Volltextzugriff (PDF)

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2569-2575

2015

Volltextzugriff (PDF)

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

Clinical cancer research, 2019-03, Vol.25 (6), p.1727-1736

2019

Volltextzugriff (PDF)

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies

Gynecologic oncology, 2018-03, Vol.148 (3), p.507-514

2018

Volltextzugriff (PDF)

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

Gynecologic oncology, 2018-10, Vol.151 (1), p.46-52

2018

Volltextzugriff (PDF)

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer

Future oncology (London, England), 2018-01, Vol.14 (2), p.123-136

2018

Volltextzugriff (PDF)

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Gynecologic oncology, 2017-11, Vol.147 (2), p.402-407

2017

Volltextzugriff (PDF)

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

The New England journal of medicine, 2023-12, Vol.389 (23), p.2162-2174

2023

Volltextzugriff (PDF)

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Journal of clinical oncology, 2016-07, Vol.34 (19), p.2279-2286

2016

Volltextzugriff (PDF)

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer

Gynecologic oncology, 2024-06, Vol.185, p.186-193

2024

Volltextzugriff (PDF)

Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition

Journal of clinical oncology, 2007-07, Vol.25 (20), p.2894-2901

2007

Volltextzugriff (PDF)

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

Clinical cancer research, 2023-04, Vol.29 (8), p.1515-1527

2023

Volltextzugriff (PDF)

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic oncology, 2018-09, Vol.150 (3), p.466-470

2018

Volltextzugriff (PDF)

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

Gynecologic oncology, 2019-12, Vol.155 (3), p.420-428

2019

Volltextzugriff (PDF)

Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

Seminars in oncology, 2009-04, Vol.36 (2), p.112-125

2009

Volltextzugriff (PDF)

A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors

Nature communications, 2023-07, Vol.14 (1), p.4513-4513, Article 4513

2023

Volltextzugriff (PDF)

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis

Journal of the National Comprehensive Cancer Network, 2017-10, Vol.15 (10), p.1224

2017

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(89)

Publikationsform

Artikel
(100)
Bücher
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Life Sciences & Biomedicine
(41)
Humans
(40)
Oncology
(38)
Female
(37)
Aged
(18)
Middle Aged
(18)
Ovarian Neoplasms - Drug Therapy
(18)
Adult
(15)
Obstetrics & Gynecology
(14)
Ovarian Cancer
(13)
Aged, 80 And Over
(11)
Ovarian Neoplasms - Pathology
(10)
Tumors
(10)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(8)
Chemotherapy
(8)
Disease-Free Survival
(8)
Neoplasm Recurrence, Local - Drug Therapy
(7)
Antineoplastic Agents - Therapeutic Use
(6)
Drug Resistance, Neoplasm
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Platinum Resistance: The Role of DNA Repair Pathways

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age?

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer

Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis

Suchergebnisse filtern